- Home
- NEGG vs IPHA Comparison
NEGG vs IPHA Comparison
Compare NEGG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | IPHA |
|---|---|---|
| Founded | 2001 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 174.2M |
| IPO Year | 2010 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NEGG | IPHA |
|---|---|---|
| Price | $57.13 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 171.7K | 21.7K |
| Earning Date | 12-01-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,313,127,000.00 | $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.32 | $1.47 |
| 52 Week High | $137.84 | $3.51 |
Technical Indicators
Market Signals| Indicator | NEGG | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 46.44 |
| Support Level | $61.75 | $1.85 |
| Resistance Level | $79.60 | $1.91 |
| Average True Range (ATR) | 6.01 | 0.07 |
| MACD | -2.11 | 0.00 |
| Stochastic Oscillator | 2.11 | 28.54 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.